Akeso Approved to Market PD-1 in China as First-Line NSCLC Therapy

Guangzhou Akeso was approved to market penpulimab, an anti PD-1 mAb, as a first-line treatment in China for squamous non-small cell lung cancer. Akeso co-developed the drug with Sino Biopharma. In August, 2021, the drug was approved as a third line therapy to treat classic Hodgkin's lymphoma. Last month, Akeso out-licensed ex-China rights for its bispecific PD-1/VEGF candidate to California's Summit Therapeutics in a deal worth up to $5 billion ($500 million upfront). Akeso develops first-in-class and best-in-class medicines for global markets. More details....

STock Symbols: (HK: 9926) (HK: 1177)

Share this with colleagues: